The HSD also showed alarming inefficiency in implementing different projects.
According to the report, HSD received Tk 6,447.78 crore as project aid from ADP and could utilise only Tk 664.94 crore, which is 10.31 percent of the allocated project aid.
This is also one of the lowest among 48 ministries and divisions that received project aid.
HSD was allocated Tk 5,531.56 crore from the government s own fund to implement different projects.
It could utilise only Tk 1,850 crore, which is 33.45 percent of the allocation also one of the lowest among ministries and divisions.
Experts expressed concern over HSD s inefficiency in a time of pandemic and grave crises in health services.
DHAKA: Bangladesh has joined the global coronavirus disease (COVID-19) vaccine race with the announcement on Thursday by the producer of its Bongavax that clinical trials were due to start next month.
In late December, the country’s Directorate General of Drug Administration (DGDA) permitted Dhaka-based Globe Biotech Ltd., the developer of Bongavax, to produce the country’s first locally made COVID-19 vaccine.
Previously called Bancovid, the vaccine has been included in the draft landscape of the World Health Organization’s (WHO) COVID-19 vaccine candidates.
Asif Mahmud, who is in charge of Globe Biotech’s research, told Arab News: “We are expecting to go for clinical trial by next month.